Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease

CLEVELAND, July 28 /PRNewswire/ -- More than 340,000(2) women suffer from postmenopausal osteoporosis (PMO) in Ohio and more than 900,000(3) are at risk for the disease. According to a census report on the prevalence of osteoporosis, the number of women suffering from the...

Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound

SOUTH SAN FRANCISCO, Calif., March 2 /PRNewswire-FirstCall/ -- Hana Biosciences (Nasdaq: HNAB ) today announced that an Independent Data Monitoring Committee (IDMC) has completed a planned, pre-specified safety review of interim data from the ongoing pivotal rALLy clinical trial of Marqibo(R...

Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)

Preclinical Results Show Neo-Bladder Replacement Structurally Similar to Native Bladder by Six Months; Data Presented at May 18 Press Briefing and Poster Session ORLANDO, Fla. and EAST NORRITON, Pa., May 19 /PRNewswire/ -- Tengion, Inc., a clinical stage biotechnol...

Preclinical Study Shows CTI's Brostallicin's Cancer-Killing Ability Based on Genetic Profiling

Data presented at AACR 2008 SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Systems Medicine LLC (SM), a wholly owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC), presented data from a preclinical study demonstrating that the Company's experimental d...

Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin

DALLAS, Dec. 7 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it has demonstrated the ability, using the company's proprietary Cobalamin(TM) technology, to significantly reduce glucose levels in an animal model of diabetes, through its or...

Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice

Positive Findings Support Preclinical Development of Intradigm's ICS-283 PALO ALTO, Calif., Oct. 24 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced study results that demonstrated the company's TargeTran(TM)...

Advanced Cell Technology's Ability to Rescue Vision in Blind Rats Noted in Scientific American

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar 5, 2007 - Advanced Cell Technology, Inc.'s (OTCBB: ACTC) ability to rescue vision in blind rats was noted in Scientific American's March 2007 issue as the lead story of its News Scan section. The full text of the article, which notes Advanced Cell's ability to ...

Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics

Three Oritavancin Studies Presented at ECCMID/ICC MUNICH, Germany, April 03, 2007 /PRNewswire/ -- Targanta Therapeutics today announced results from two studies showing the improved potency of oritavancin to stop bacterial growth in vitro when tested with a common wetting agent (polysorbate 80) an...

AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin Cells Have the Ability to Recognize, Transport and Utilize L-ergothioneine (EGT) As A Protector Against Oxidative Damage

Clinical Poster Presented at Society for Investigative Dermatology FREEPORT, N.Y., May 16, 2007 /PRNewswire/ -- AGI Dermatics recently announced new comparative clinical data that indicates that OCTN-1 skin cells have the ability to recognize, transport and utilize L-ergothioneine (EGT) as a prote...

Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - Elixir Pharmaceuticals, Inc., announced today the publication of clinical data highlighting the ability of Glufast(R) (mitiglinide calcium hydrate) monotherapy, or combination therapy with metformin, to manage glucose surges before and after meals. ...

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

...hift in the way physicians will deliver drugs to all organ systems in the future. "The implantation of this kind of device on any organ and the ability to deliver medication to the affected organ, could be a huge advance in how we currently treat cancer," Dr. Murphree said. This work is done in conjun...

Regular Yoga Practice Is Associated With Mindful Eating

...e to hold a challenging physical pose by observing the discomfort in a non-judgmental way, with an accepting, calm mind and focus on the breath. "This ability to be calm and observant during physical discomfort teaches how to maintain calm in other challenging situations, such as not eating more even when th...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

... offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially succ...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

...ntiation in developing tissues and appear to play an important role in regulating bone remodeling in adults. While both peptides have demonstrated the ability to increase bone mineral density and bone strength in humans, PTHrP and its analogs do not stimulate adverse bone resorption and hypercalcemia to the ...

NewCardio Announces Master Services Agreement With Dedicated Phase I

...d in assessing cardiac status while increasing the ability to diagnose clinically significant conditions whic...nefits to be derived from personnel and directors, ability to commercialize our products, our assumptions reg...s, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed,...

Labopharm files New Drug Submission with Health Canada for novel antidepressant

...mc.com ). Major depressive disorder (MDD) is a common mental illness often characterized by a combination of symptoms that interfere with a person's ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Approximately 8% of adults will experience major depression at some time in their l...

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

...tions at Novavax, commented, "Demonstration of our ability to construct and produce GMP-quality influenza vac...e risks and uncertainties, including the Company's ability to progress any product candidates in preclinical ...nt venture and licensing agreements; the Company's ability to enter into future collaborations with industry ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially succ...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...m/mnr/janssen/39116/ An estimated one percent of the world's population suffers from schizophrenia - a brain disorder that impairs a person's ability to think clearly, relate to others, and distinguish between reality and imagination. While there is no cure for schizophrenia, the symptoms and the ri...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

...didates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Acc...of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These s...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

...d Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercia...egulation of the Company's products; the Company's ability to manufacture its products in sufficient quantiti...therapies on the Company's products; the Company's ability to register, maintain and enforce patents and othe...

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

...ental authorities, the possibility that the FDA will not approve a phase III registration strategy for paclitaxel poliglumex if proposed by CTI, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, and costs of developing, producing and...

Covance Receives Highest Level of Phase I Accreditation

...mitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described...

New Powder Speeds Healing of Difficult Foot Wounds

...can Podiatric Medical Association's (APMA) 97th Annual Scientific Meeting in Toronto, July 30 - August 2, 2009, and will highlight the powder's unique ability to rapidly heal foot wounds and advance the treatment patients currently receive. (Logo: http://www.newscom.com/cgi-bin/prnh/20090730/DC54472LOGO ...

Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty-Plus Year Historic Relationship

...s forward looking and fortifies each of our missions and core programs," said Steven M. Safyer, MD, president and CEO of Montefiore. "It enhances our ability to recruit the best and brightest faculty and clinical staff in the nation; to spearhead new clinical trials in areas such as heart disease, cancer, p...

European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK

... operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet custome...gulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potential...

Treatment Shows Excellent Results for Providence Tarzana Patients Following Cardiac Arrest

...oncerted effort to go hospital-wide with the process so that anyone who has a cardiac arrest in the local community or arrests in the hospital has the ability to benefit from the protocol," Dr. Brewster said. About Providence Health & Services Providence Health & Services, California, ...

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

...d Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercia...egulation of the Company's products; the Company's ability to manufacture its products in sufficient quantiti...therapies on the Company's products; the Company's ability to register, maintain and enforce patents and othe...

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

...t of psychiatry at Massachusetts General Hospital and professor of psychiatry at Harvard Medical School. "Researchers have speculated that the brain's ability to grow new brain cells may have an impact on depression, and we now know that we can stimulate the natural process of neurogenesis with a positive cl...

Cryo-Cell Announces C'elle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.

...ontinence, a condition primarily caused by a deficiency in the muscles that affect urine flow. Since stem cells isolated from menstrual fluid have the ability to contract, research will determine whether injecting the cells into the urethra would restore the contractility of the muscles and sphincters. ...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

...-mutated rats also carried the modifications, demonstrating the genetic changes were permanent and heritable. Together, these results demonstrate the ability to deliver engineered ZFNs into early-stage embryos and rapidly generate heritable, knockout mutations in a whole organism. Rats are physiolo...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

... a history of eye problems should be monitored by their health care provider. Use ASMANEX as directed by your health care provider, since its ability to work in your lungs depends on regular use. Maximum benefit may take 1 to 2 weeks or longer. If your asthma symptoms do not improve, or get worse, c...

Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing

...ated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property righ...k of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in te...

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA

...urrent assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1032 and preclinical and clinical development of its other potential drug candidates, advance ad...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

...; unexpected regulatory actions or delays or government regulation generally; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values att...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

...s evaluating its product candidates; the company's ability to obtain additional funding required to conduct i... in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other i...

Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study

...s and products; control of costs and expenses; our ability to obtain and maintain adequate intellectual property protection; our ability to successfully integrate acquired businesses; our ability to form and implement alliances; challenges relati...

Teeth and Gums Also Benefit from the Healing Power of Aloe Vera

...era plant has a long history of healing power. Its ability to heal burns and cuts and soothe pain has been do...a -- disease-causing bacteria -- in the mouth. The ability of aloe vera tooth gel to successfully perform tha...als. However, the study compared the germ-fighting ability of an aloe vera tooth gel to two commercially popu...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

...nts because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, i...

Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity

...n and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement...